The History of Patenting Genetic Material
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The US Supreme Court's recent decision in Association for Molecular Pathology v. Myriad Genetics, Inc. declared, for the first time, that isolated human genes cannot be patented. Many have wondered how genes were ever the subjects of patents. The answer lies in a nuanced understanding of both legal and scientific history. Since the early twentieth century, “products of nature” were not eligible to be patented unless they were “isolated and purified” from their surrounding environment. As molecular biology advanced, and the capability to isolate genes both physically and by sequence came to fruition, researchers (and patent offices) began to apply patent-law logic to genes themselves. These patents, along with other biological patents, generated substantial social and political criticism. Myriad Genetics, a company with patents on BRCA1 and BRCA2, two genes critical to assessing early-onset breast and ovarian cancer risk, and with a particularly controversial business approach, became the antagonist in an ultimately successful campaign to overturn gene patents in court. Despite Myriad's defeat, some questions concerning the rights to monopolize genetic information remain. The history leading to that defeat may be relevant to these future issues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Viral RNA-dependent DNA Polymerase: RNA-dependent DNA Polymerase in Virions of RNA Tumour Viruses
BALTIMORE, D. (1970) · Nature · doi:10.1038/2261209a0 · Cited by 2,068 · cited 1×
“The 1960s and 1970s realized major advances in molecular biology, including the elucidation of the genetic code (69), the discovery of reverse transcriptase (12), and the first successful sequence-specific synthesis of a DNA molecule (97).”
Background
Cited by
Sorbara, M. T., & Pamer, E. G. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00667-9 · Cited by 468
Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens
Pamer, E. G. (2016) · Science · doi:10.1126/science.aad9382 · Cited by 418
Genome editing with the CRISPR‐Cas system: an art, ethics and global regulatory perspective
Zhang, D., Hussain, A., Manghwar, H., Xie, K., Xie, S., Zhao, S., Larkin, R. M., Qing, P., Jin, S., & Ding, F. (2020) · Plant Biotechnology Journal · doi:10.1111/pbi.13383 · Cited by 233
“After several years of controversy, the US Supreme Court in 2013 set a rule that human genes cannot be patented because the DNA is a ‘product of nature’ (Joly and Tonin, 2014; Sherkow and Greely, 2015).”
BackgroundSnipping around for food: economic, ethical and policy implications of CRISPR/Cas genome editing
Bartkowski, B., Theesfeld, I., Pirscher, F., & Timaeus, J. (2018) · Geoforum · doi:10.1016/j.geoforum.2018.07.017 · Cited by 81
How does emerging patent case law in the US and Europe affect precision medicine?
Aboy, M., Liddell, K., Crespo, C., Cohen, I. G., Liddicoat, J., Gerke, S., & Minssen, T. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0265-1 · Cited by 20
Metadata
- Authors
- Sherkow, J. S., & Greely, H. T.
- Venue
- Annual Review of Genetics
- Publisher
- Annual Reviews
- Published
- 2015-11-23
- Volume
- 49
- Issue
- 1
- Pages
- 161-182
- ISSN
- 0066-4197 (ISSN-L)
- 1545-2948
- OpenAlex
- W2116519007
- Cited by
- 63
- References
- 1
- FWCI
- 23.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The History of Patenting Genetic Material. https://app.cochat.ai/papers/10.1146/annurev-genet-112414-054731
- The paper
- Sherkow, J. S., & Greely, H. T. (2015). The History of Patenting Genetic Material. Annual Review of Genetics. https://doi.org/10.1146/annurev-genet-112414-054731
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.